TrialBMC infectious diseases2012

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.

Emanuele Focà et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.